poisar

Stocks · News reference

BMO Capital Maintains Outperform on Hamilton Lane, Lowers Price Target to $95

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HLNE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    FDA approves Cosette Pharmaceuticals' EVOXAC

    – – New Oral Solution Formulation Developed for Patients Living with Sjögren’s Disease demonstrates Cosette's expanding capabilities in product development and innovation – –– – Product Expected to be Commercially

    HLNE
  2. SEC EDGAR

    8-K filing — Hamilton Lane INC (HLNE)

    Filed: 2026-10-15 AccNo: 0001433642-26-000048 Size: 166 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    HLNE